Citalopram
- Generic Name
- Citalopram
- Brand Names
- Celexa, Ctp
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 59729-33-8
- Unique Ingredient Identifier
- 0DHU5B8D6V
- Background
Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the i...
- Indication
Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.
- Associated Conditions
- Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)
- Associated Therapies
- -
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- PharmaNeuroBoost N.V.
- Target Recruit Count
- 555
- Registration Number
- NCT01312922
- Locations
- 🇺🇸
Site 108, Winter Park, Florida, United States
🇺🇸Site 133, Atlanta, Georgia, United States
🇺🇸Site 110, Baltimore, Maryland, United States
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
- Conditions
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- Columbia Northwest Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT01189812
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Northwest Clinical Research Center, Bellevue, Washington, United States
A Study of Medication With or Without Psychotherapy for Complicated Grief
- Conditions
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 395
- Registration Number
- NCT01179568
- Locations
- 🇺🇸
VASDHS / University of California San Diego, San Diego, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
- Conditions
- Interventions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2010-07-01
- Lead Sponsor
- Vrije Universiteit Brussel
- Target Recruit Count
- 70
- Registration Number
- NCT01154647
- Locations
- 🇧🇪
University Hospital Antwerp, Edegem, Antwerp, Belgium
Study of Treatment of Depression in Refractory Asthma
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Liam Heaney
- Target Recruit Count
- 40
- Registration Number
- NCT01153165
- Locations
- 🇬🇧
Regional Respiratory Centre, Belfast City Hospital, Belfast, United Kingdom
Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression
- Conditions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2016-01-28
- Target Recruit Count
- 7
- Registration Number
- NCT01099592
- Locations
- 🇨🇦
Montreal Heart Insitute, Montreal, Quebec, Canada
🇨🇦Centre de recherche du CHUM, Montreal, Quebec, Canada
DECIFER: Depression and Citalopram In First Episode Recovery
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 95
- Registration Number
- NCT01041274
- Locations
- 🇺🇸
New York University Langone Medical Center/ Bellevue Hospital, New York, New York, United States
Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 62
- Registration Number
- NCT01032083
- Locations
- 🇬🇧
Avon and Wiltshire mental health partnership, Bristol, United Kingdom
🇬🇧Lincolnshire partnership NHS foundation trust, Lincoln, United Kingdom
🇬🇧Manchester health and social care trust, Manchester, United Kingdom
Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Zentrum für Integrative Psychiatrie
- Target Recruit Count
- 45
- Registration Number
- NCT00993876
- Locations
- 🇩🇪
Zentrum für Integrative Psychiatrie, Kiel, Germany
N-methylglycine (Sarcosine) Treatment for Depression
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00977353
- Locations
- 🇨🇳
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.